← All drugs
Drug · FAERS side-effect profile with label screen

Warfarin side effects: what 126,271 FDA adverse event reports show

Warfarin · Warfarin Sodium · 1,227 reaction terms · 479,177 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Not stated in label

Brand names

Warfarin Sodium

openFDA label

Who reports

126,271 reports · 80% serious · 16,103 with death outcome · 49% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Warfarin sodium tablets are indicated for: Prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (PE). Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation (AF) and/or cardiac valve replacement.

FDA label, Indications and Usage

What it is

4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one is a member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.

PubChem CID 54678486 (ChEBI)

Boxed warning

BLEEDING RISK Warfarin sodium can cause major or fatal bleeding [see Warnings and Precautions (5.1) ] . Perform regular monitoring of INR in all treated patients [see Dosage and Administration (2.1) ] . Drugs, dietary changes, and other factors affect INR levels achieved with warfarin sodium therapy [see Drug Interactions (7) ] .

FDA label
How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled — boxed warning 2Labeled (related wording) 2Reporting / coding artifact 6Lab value / disease marker 11Not in label — unassessed 19
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,187 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Appendicolith267402.6
322.0–503.4ROR 403.5 · calibrated p 1e-12 ✓
115.7 EB05 104.5 · IC025 +6.4
3/3 methods agree
Not in label — unassessedserious n=267 · ♀ 0% (drug 49%) · 100% clinicianno trial arm names this drug
Anticoagulation drug level above therapeutic972287.3
258.8–318.9ROR 289.5 · calibrated p 1e-11 ✓
104.4 EB05 99.0 · IC025 +6.5
3/3 methods agree
Lab value / disease markerserious n=831 · 95% clinicianno trial arm names this drug
Anticoagulation drug level below therapeutic378160.3
139.1–184.7ROR 160.8 · calibrated p 3e-9 ✓
81.0 EB05 74.3 · IC025 +6.0
3/3 methods agree
Lab value / disease markerserious n=322 · 92% clinicianno trial arm names this drug
Sleep disorder therapy90155.9
116.8–208.2ROR 156.0 · calibrated p 7e-9 ✓
78.8 EB05 66.1 · IC025 +5.5
3/3 methods agree
Reporting / coding artifactserious n=90 · ♀ 0% (drug 49%) · 100% clinicianno trial arm names this drug
Calciphylaxis729110.2
100.4–121.1ROR 110.9 · calibrated p 5e-8 ✓
66.0 EB05 62.1 · IC025 +5.9
3/3 methods agree
Labeled — boxed warning
exact term
serious n=728 · ♀ 70% (drug 49%) · 100% clinicianno trial arm names this drug
International normalised ratio abnormal1,26595.2
88.9–102.1ROR 96.2 · calibrated p 2e-7 ✓
60.4 EB05 57.7 · IC025 +5.8
3/3 methods agree
Lab value / disease markerserious n=931no trial arm names this drug
International normalised ratio increased10,35893.4
91.2–95.6ROR 101.7 · calibrated p 1e-7 ✓
59.7 EB05 58.8 · IC025 +5.9
3/3 methods agree
Labeled — boxed warning
synonym match
age-adj. PRR 59.9 · serious PRR 44.0no trial arm names this drug
International normalised ratio decreased1,36883.6
78.3–89.2ROR 84.5 · calibrated p 4e-7 ✓
55.5 EB05 53.1 · IC025 +5.7
3/3 methods agree
Lab value / disease markerserious n=1,053no trial arm names this drug
Analgesic therapy10080.2
63.1–101.9ROR 80.3 · calibrated p 8e-7 ✓
53.6 EB05 45.3 · IC025 +5.1
3/3 methods agree
Reporting / coding artifactserious n=100 · ♀ 0% (drug 49%) · 100% clinicianno trial arm names this drug
Drug therapy9974.3
58.6–94.2ROR 74.4 · calibrated p 1e-6 ✓
50.9 EB05 43.0 · IC025 +5.0
3/3 methods agree
Reporting / coding artifactserious n=99 · ♀ 0% (drug 49%) · 100% clinicianno trial arm names this drug
International normalised ratio fluctuation59565.7
59.8–72.3ROR 66.0 · calibrated p 2e-6 ✓
47.1 EB05 44.0 · IC025 +5.4
3/3 methods agree
Lab value / disease markerserious n=377no trial arm names this drug
Steroid dependence17442.6
36.1–50.3ROR 42.7 · calibrated p 4e-5 ✓
33.9 EB05 29.8 · IC025 +4.7
3/3 methods agree
Not in label — unassessedserious n=174 · ♀ 0% (drug 49%) · 100% clinicianno trial arm names this drug
Catarrh15936.0
30.3–42.8ROR 36.1 · calibrated p 1e-4 ✓
29.6 EB05 25.9 · IC025 +4.5
3/3 methods agree
Not in label — unassessedserious n=159 · ♀ 0% (drug 49%) · 100% clinicianno trial arm names this drug
Prothrombin time abnormal10830.6
24.9–37.6ROR 30.6 · calibrated p 3e-4 ✓
25.8 EB05 22.0 · IC025 +4.2
3/3 methods agree
Lab value / disease markerserious n=67no trial arm names this drug
Spinal epidural haematoma8629.7
23.6–37.4ROR 29.8 · calibrated p 3e-4 ✓
25.2 EB05 21.0 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious n=86 · ♀ 100% (drug 49%) · 100% clinicianno trial arm names this drug
Abdominal wall haematoma28528.4
25.0–32.2ROR 28.4 · calibrated p 4e-4 ✓
24.3 EB05 22.0 · IC025 +4.3
3/3 methods agree
Not in label — unassessedserious n=278 · 100% clinicianno trial arm names this drug
Coagulation time prolonged22828.3
24.6–32.6ROR 28.4 · calibrated p 4e-4 ✓
24.2 EB05 21.7 · IC025 +4.3
3/3 methods agree
Lab value / disease markerserious n=214 · 100% clinicianno trial arm names this drug
Prothrombin time prolonged77124.2
22.4–26.0ROR 24.3 · calibrated p 8e-4 ✓
21.2 EB05 19.9 · IC025 +4.3
3/3 methods agree
Lab value / disease markerserious n=691no trial arm names this drug
Retroperitoneal haematoma26823.0
20.2–26.1ROR 23.0 · calibrated p 0.001 ✓
20.2 EB05 18.3 · IC025 +4.1
3/3 methods agree
Not in label — unassessedserious n=266 · 100% clinicianno trial arm names this drug
Coagulation test abnormal8621.0
16.8–26.3ROR 21.0 · calibrated p 0.002 ✓
18.7 EB05 15.6 · IC025 +3.7
3/3 methods agree
Reporting / coding artifactserious n=83 · ♀ 100% (drug 49%) · 100% clinicianno trial arm names this drug
Intra-abdominal haematoma13520.1
16.8–24.1ROR 20.2 · calibrated p 0.002 ✓
18.0 EB05 15.6 · IC025 +3.8
3/3 methods agree
Not in label — unassessedserious n=134 · 100% clinicianno trial arm names this drug
Retroperitoneal haemorrhage26119.5
17.2–22.2ROR 19.6 · calibrated p 0.002 ✓
17.5 EB05 15.8 · IC025 +3.9
3/3 methods agree
Not in label — unassessedserious n=257 · 100% clinicianno trial arm names this drug
Labelled drug-drug interaction medication error87818.0
16.8–19.3ROR 18.1 · calibrated p 0.003 ✓
16.3 EB05 15.4 · IC025 +3.9
3/3 methods agree
Reporting / coding artifactserious PRR 13.3no trial arm names this drug
Gastric haemorrhage1,08117.0
16.0–18.1ROR 17.1 · calibrated p 0.004 ✓
15.5 EB05 14.7 · IC025 +3.8
3/3 methods agree
Not in label — unassessedserious PRR 11.1 · ♀ 10% (drug 49%) · 94% clinicianno trial arm names this drug
Catheter management8417.0
13.5–21.2ROR 17.0 · calibrated p 0.005 ✓
15.4 EB05 12.8 · IC025 +3.5
3/3 methods agree
Reporting / coding artifactserious n=80 · ♀ 100% (drug 49%) · 100% clinicianno trial arm names this drug
Cardioactive drug level increased12116.6
13.7–20.0ROR 16.6 · calibrated p 0.005 ✓
15.1 EB05 12.9 · IC025 +3.5
3/3 methods agree
Lab value / disease markerserious n=116 · 100% clinicianno trial arm names this drug
Burns second degree15716.3
13.8–19.2ROR 16.3 · calibrated p 0.005 ✓
14.9 EB05 13.0 · IC025 +3.6
3/3 methods agree
Not in label — unassessedserious n=157 · ♀ 0% (drug 49%) · 100% clinicianno trial arm names this drug
Subdural haemorrhage23715.6
13.6–17.8ROR 15.6 · calibrated p 0.006 ✓
14.3 EB05 12.8 · IC025 +3.6
3/3 methods agree
Not in label — unassessedserious n=234no trial arm names this drug
Haematoma muscle10115.5
12.6–19.0ROR 15.5 · calibrated p 0.007 ✓
14.2 EB05 12.0 · IC025 +3.4
3/3 methods agree
Not in label — unassessedserious n=99 · ♀ 0% (drug 49%) · 100% clinicianno trial arm names this drug
Haemorrhage intracranial1,26615.2
14.4–16.1ROR 15.4 · calibrated p 0.006 ✓
14.0 EB05 13.4 · IC025 +3.7
3/3 methods agree
Not in label — unassessedserious PRR 10.0 · 95% clinicianno trial arm names this drug
Blood phosphorus increased21714.3
12.4–16.4ROR 14.3 · calibrated p 0.009 ✓
13.2 EB05 11.8 · IC025 +3.5
3/3 methods agree
Lab value / disease markerserious n=215 · ♀ 0% (drug 49%) · 100% clinicianno trial arm names this drug
Subdural haematoma1,14114.3
13.4–15.1ROR 14.4 · calibrated p 0.008 ✓
13.2 EB05 12.5 · IC025 +3.6
3/3 methods agree
Not in label — unassessedserious PRR 9.4 · 93% clinicianno trial arm names this drug
Catheter site discharge8413.7
10.9–17.1ROR 13.7 · calibrated p 0.011 ✓
12.5 EB05 10.4 · IC025 +3.2
3/3 methods agree
Not in label — unassessedserious n=76 · ♀ 100% (drug 49%)no trial arm names this drug
Muscle haemorrhage30513.6
12.1–15.3ROR 13.6 · calibrated p 0.010 ✓
12.6 EB05 11.5 · IC025 +3.4
3/3 methods agree
Not in label — unassessedserious n=303 · 91% clinicianno trial arm names this drug
Occult blood positive14913.3
11.3–15.8ROR 13.4 · calibrated p 0.012 ✓
12.3 EB05 10.7 · IC025 +3.3
3/3 methods agree
Lab value / disease markerserious n=142 · 100% clinicianno trial arm names this drug
Catheter site erythema15513.2
11.2–15.5ROR 13.2 · calibrated p 0.012 ✓
12.2 EB05 10.7 · IC025 +3.3
3/3 methods agree
Not in label — unassessedserious n=134 · ♀ 76% (drug 49%)no trial arm names this drug
Peritoneal haemorrhage10112.8
10.4–15.6ROR 12.8 · calibrated p 0.014 ✓
11.8 EB05 9.9 · IC025 +3.2
3/3 methods agree
Not in label — unassessedserious n=101 · 100% clinicianno trial arm names this drug
Hyperphosphataemia15012.6
10.7–14.8ROR 12.6 · calibrated p 0.015 ✓
11.7 EB05 10.2 · IC025 +3.2
3/3 methods agree
Not in label — unassessedserious n=147 · ♀ 0% (drug 49%) · 100% clinicianno trial arm names this drug

Clinical concept groups

MedDRA splits one clinical problem across several terms (e.g. "neutropenia", "neutrophil count decreased", "agranulocytosis"), which dilutes term-level signals. These rows count reports with any term in a concept group (an exact union, not a sum), compared with all other drugs. Groups are hand-built and listed in the methods.

ConceptReportsPRR 95% CIReading
Gi bleeding6,7386.36.2–6.5signal
Arrhythmia / qt4,9774.44.2–4.5signal
Heart failure4,4164.24.1–4.3signal
Venous thromboembolism5,0814.03.9–4.1signal
Anaemia6,7123.83.7–3.9signal
Stroke4,5583.13.0–3.2signal
Kidney injury7,2192.72.6–2.7signal
Hyponatraemia1,2292.62.4–2.7signal
Fall / fracture5,1282.32.2–2.3signal
Rhabdomyolysis / myopathy9482.01.8–2.1raised
Serious infection8,8711.91.9–2.0raised
Thrombocytopenia2,1581.61.6–1.7raised
Interstitial lung disease9231.61.5–1.7raised
Myocardial infarction1,7421.41.4–1.5raised
Hypoglycaemia7811.41.3–1.5raised
Liver injury2,0281.11.1–1.2raised

Trial evidence (ClinicalTrials.gov)

No completed trial with posted adverse-event results was found on ClinicalTrials.gov for Warfarin (searched WARFARIN).

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
International normalised ratio increased10,35893.4
91.2–95.6ROR 101.7 · calibrated p 1e-7 ✓
59.7 EB05 58.8 · IC025 +5.9
3/3 methods agree
Labeled — boxed warning
synonym match
age-adj. PRR 59.9 · serious PRR 44.0no trial arm names this drug
Dyspnoea (shortness of breath)8,5032.5
2.5–2.6ROR 2.6 · calibrated p 0.760
2.5 EB05 2.5 · IC025 +1.3
3/3 methods agree
Not in label — unassessedage-adj. PRR 2.1 · serious PRR 2.1no trial arm names this drug
Drug interaction6,3636.9
6.7–7.1ROR 7.2 · calibrated p 0.091
6.7 EB05 6.5 · IC025 +2.7
3/3 methods agree
Reporting / coding artifactage-adj. PRR 5.4 · serious PRR 5.0no trial arm names this drug
Fatigue (tiredness)6,2331.3
1.3–1.4ROR 1.4 · calibrated p 0.543
1.3 EB05 1.3 · IC025 +0.4Not in label — unassessedage-adj. PRR 1.2 · serious PRR 1.3no trial arm names this drug
Nausea6,0071.3
1.2–1.3ROR 1.3 · calibrated p 0.494
1.3 EB05 1.2 · IC025 +0.3Labeled adverse reaction
exact term
age-adj. PRR 1.2 · serious PRR 1.3no trial arm names this drug
Diarrhoea (diarrhea)5,9711.5
1.5–1.6ROR 1.6 · calibrated p 0.689
1.5 EB05 1.5 · IC025 +0.6Labeled adverse reaction
exact term
age-adj. PRR 1.3 · serious PRR 1.4no trial arm names this drug
Dizziness5,2101.7
1.7–1.8ROR 1.8 · calibrated p 0.816
1.7 EB05 1.7 · IC025 +0.8Not in label — unassessedage-adj. PRR 1.5 · serious PRR 1.7no trial arm names this drug
Drug ineffective (drug did not work)5,1960.7
0.6–0.7ROR 0.6 · calibrated p 0.101
0.7 EB05 0.6 · IC025 -0.7
PRR-only: not supported by EBGM or IC
Reporting / coding artifactage-adj. PRR 0.8 · serious PRR 0.9no trial arm names this drug
Fall4,8532.4
2.4–2.5ROR 2.5 · calibrated p 0.812
2.4 EB05 2.4 · IC025 +1.2
3/3 methods agree
Not in label — unassessedage-adj. PRR 1.7 · serious PRR 1.9no trial arm names this drug
Death4,7650.9
0.9–0.9ROR 0.9 · calibrated p 0.252
0.9 EB05 0.9 · IC025 -0.2
PRR-only: not supported by EBGM or IC
Outcome field, not a reaction
boxed warning mentions mortality
age-adj. PRR 0.8 · serious PRR 0.7no trial arm names this drug
Headache4,7291.3
1.2–1.3ROR 1.3 · calibrated p 0.485
1.3 EB05 1.2 · IC025 +0.3Not in label — unassessedage-adj. PRR 1.3 · serious PRR 1.3no trial arm names this drug
Asthenia (weakness)4,4032.0
1.9–2.0ROR 2.0 · calibrated p 0.939
1.9 EB05 1.9 · IC025 +0.9Not in label — unassessedage-adj. PRR 1.6 · serious PRR 1.7no trial arm names this drug
Pneumonia (lung infection)4,1552.1
2.1–2.2ROR 2.2 · calibrated p 0.957
2.1 EB05 2.1 · IC025 +1.0
3/3 methods agree
Not in label — unassessedage-adj. PRR 1.7 · serious PRR 1.6no trial arm names this drug
Haemorrhage4,0596.7
6.5–6.9ROR 6.9 · calibrated p 0.105
6.4 EB05 6.3 · IC025 +2.6
3/3 methods agree
Labeled — boxed warning
exact term
age-adj. PRR 6.8 · serious PRR 5.3no trial arm names this drug
Off label use (used outside approved label)3,9810.8
0.7–0.8ROR 0.8 · calibrated p 0.158
0.8 EB05 0.7 · IC025 -0.4
PRR-only: not supported by EBGM or IC
Reporting / coding artifactage-adj. PRR 0.7 · serious PRR 0.8no trial arm names this drug

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Warfarin ↔ INR increased.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Warfarin?

In FDA FAERS, the most frequently co-reported reaction terms for Warfarin are international normalised ratio increased, dyspnoea, fatigue, nausea, diarrhoea, dizziness. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Warfarin have an FDA boxed warning?

Yes. The current FDA label carries a boxed warning: BLEEDING RISK Warfarin sodium can cause major or fatal bleeding [see Warnings and Precautions (5.1) ] . Perform regular monitoring of INR in all treated patients [see Dosage and Administration (2.1) ] . Drugs, dietary changes, and other factors affect INR levels achieved with warfarin sodium therapy [see Drug Interactions (7) ] .

Do FAERS signals prove that Warfarin causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.